Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

Fig. 1

ERBB4 mutation are tightly associated with the prognosis of NSCLC. AI The prevalence of ERBB4 and TP53 mutations in NSCLC patients based on the cBioPortal for Cancer Genomics; AII The whole protein and specific changes of ERBB4 in the cohorts. B The relationship between ERBB4 mutation status and progress free survival (PFS) of NSCLC patients treated by ICIs; C The relationship between ERBB4 mutation status and overall survival (OS) of NSCLC patients treated by ICIs. D The relationship between ERBB4 mutation status and OS of LUAD patients treated by non-ICIs from the TCGA cohort. E The relationship between ERBB4 mutation status and OS of LUSC patients treated by non-ICIs from the TCGA cohort

Back to article page

Molecular Medicine

ISSN: 1528-3658